Biogen Inc. $BIIB Shares Sold by NewEdge Advisors LLC

Posted by on Aug 15th, 2026

NewEdge Advisors LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 38.1% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 13,031 shares of the biotechnology company’s stock after selling 8,017 shares during the period. NewEdge Advisors LLC’s holdings in Biogen were worth $2,389,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Caerus Investment Advisors LLC increased its holdings in Biogen by 5.0% in the first quarter. Caerus Investment Advisors LLC now owns 2,801 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 134 shares during the last quarter. Financial Solutions Advisory Group Inc. bought a new position in Biogen during the 1st quarter worth approximately $252,000. Glenmede Trust Co. NA grew its position in shares of Biogen by 17.5% in the 1st quarter. Glenmede Trust Co. NA now owns 11,652 shares of the biotechnology company’s stock worth $2,136,000 after acquiring an additional 1,733 shares in the last quarter. Groupama Asset Managment grew its position in shares of Biogen by 3.8% in the 1st quarter. Groupama Asset Managment now owns 8,753 shares of the biotechnology company’s stock worth $1,605,000 after acquiring an additional 322 shares in the last quarter. Finally, Segall Bryant & Hamill LLC bought a new stake in shares of Biogen in the 1st quarter valued at approximately $1,025,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Down 0.4%

NASDAQ:BIIB opened at $209.83 on Friday. The firm has a market capitalization of $31.00 billion, a P/E ratio of 37.14, a P/E/G ratio of 6.51 and a beta of 0.17. The business has a 50 day simple moving average of $203.76 and a 200 day simple moving average of $193.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $219.72.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period last year, the company earned $5.47 earnings per share. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts predict that Biogen Inc. will post 12.5 EPS for the current year.

Wall Street Analyst Weigh In

BIIB has been the topic of several research analyst reports. Sanford C. Bernstein reduced their price objective on Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Oppenheimer reiterated an “outperform” rating and set a $300.00 target price on shares of Biogen in a research note on Wednesday, July 29th. HC Wainwright raised their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Royal Bank Of Canada decreased their price target on shares of Biogen from $242.00 to $240.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Finally, Truist Financial raised shares of Biogen from a “hold” rating to a “buy” rating and boosted their price objective for the company from $190.00 to $235.00 in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $227.07.

Get Our Latest Research Report on Biogen

Biogen Profile

(Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Read More

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.